Dianthus Therapeutics, Inc. /DE/
DNTH · Pharmaceutical Preparations
Latest available SEC filing: 4 ·
Latest disclosures
-
Carr Edward: Form 4
Insider disclosure · Filed · Report period 17 Sep 2026
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form SCHEDULE 13G/A
SEC filing · Filed
-
Form SCHEDULE 13G
SEC filing · Filed
-
Latest financial period: Q2 2026
Financial facts · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
- DNTH · 252828108 - Common Stock, par value $0.001 per share
Company details and SEC sources
CIK 0001690585 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- DNTH on Nasdaq
- SEC industry group
- Pharmaceutical Preparations (Office of Life Sciences)
- Business address
- 7 Times Square, 43 Rd Floor, New York, NY, 10036
- Incorporated in
- DE
- Fiscal year end
- 31 December
- Former names on EDGAR
- Magenta Therapeutics, Inc. (to 08 Sep 2023)
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields